Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Enterprise Value (2020 - 2026)

GeneDx Holdings has reported Enterprise Value over the past 7 years, most recently at -$170.7 million for Q1 2026.

  • Quarterly Enterprise Value fell 7.24% to -$170.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$170.7 million through Mar 2026, down 7.24% year-over-year, with the annual reading at -$171.3 million for FY2025, 21.32% down from the prior year.
  • Enterprise Value was -$170.7 million for Q1 2026 at GeneDx Holdings, roughly flat from -$171.3 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$106.9 million in Q2 2024 and troughed at -$315.0 million in Q1 2022.
  • The 5-year median for Enterprise Value is -$155.1 million (2025), against an average of -$164.6 million.
  • The largest YoY upside for Enterprise Value was 69.06% in 2022 against a maximum downside of 973.92% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$123.9 million in 2022, then dropped by 5.01% to -$130.1 million in 2023, then dropped by 8.48% to -$141.2 million in 2024, then fell by 21.32% to -$171.3 million in 2025, then rose by 0.35% to -$170.7 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Enterprise Value are -$170.7 million (Q1 2026), -$171.3 million (Q4 2025), and -$155.1 million (Q3 2025).